The Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients With Unstable Angina and Diabetes...

Area of Science:

• Cardiology
• Inflammation Research
• Diabetes Mellitus Management

Background:

• Unstable angina (UA) incidence is rising, necessitating effective treatments for patients with diabetes mellitus (DM).
• Percutaneous coronary intervention (PCI) is vital for UA patients with DM.
• The systemic immune-inflammation index (SII) is a novel inflammation marker with prognostic implications.

Purpose of the Study:

• To evaluate the predictive value of SII for long-term prognosis in UA patients with DM post-revascularization.
• To identify factors influencing outcomes in this patient cohort.

Main Methods:

• Included 359 UA patients with DM who underwent revascularization.
• Divided patients into low SII (<622.675 × 10^9/L) and high SII (≥622.675 × 10^9/L) groups.
• Primary outcome: Major adverse cardiovascular and cerebrovascular events (MACCEs); Secondary outcome: All-cause death.

Main Results:

• High SII group had significantly higher MACCEs (24.3%) vs. low SII group (10.5%) (p < 0.001).
• Multivariate analysis identified high SII as an independent risk factor for MACCEs (HR: 0.155, p = 0.001) after adjusting for covariates.
• High SII was not a risk factor for individual events like stroke, cardiovascular death, or MI.

Conclusions:

• Elevated SII levels predict adverse outcomes in UA and DM patients post-PCI.
• Regular monitoring and management of inflammation may enhance long-term prognosis.